GHK-Cu runs on NAD+ — the part nobody mentions
The copper peptide kicks off a big repair program that needs fuel. Here's why it tends to plateau around week six.
GHK-Cu gets sold as a collagen booster, full stop. That's true the way calling a car 'a thing with wheels' is true — accurate, and almost beside the point. The copper tripeptide does something much broader than top up collagen, and understanding the breadth explains a frustration a lot of people hit around week six: it just stops working as well. The plateau isn't the compound failing. It's usually the compound running out of fuel.
It's a gene program, not a single switch
GHK-Cu doesn't merely nudge collagen synthesis up a notch. Work mapping its effects found it shifts the expression of thousands of genes in fibroblasts — moving them toward a coordinated repair and remodeling state. Collagen and elastin, yes, but also antioxidant defenses, the enzymes that remodel the extracellular matrix, and a broad set of regenerative pathways. That's why the reported effects go past 'firmer skin' into hair, wound healing, and general tissue quality. You're not flipping one dial labeled collagen; you're switching a cell into a different operating mode, and that mode touches a lot of machinery at once.
Repair has a fuel bill
Running a large, coordinated repair program is metabolically expensive. It costs the cell energy and it spends cofactors, and one of the central cofactors in that whole apparatus is NAD+ — the molecule that sits at the heart of cellular energy production and powers a long list of repair and regulatory enzymes. When you push fibroblasts to work harder for weeks on end, you are spending NAD+ faster than usual. If the supply doesn't keep up with the elevated demand, the cell can't sustain the workload you've signaled it to take on. The signal is still arriving; the cell just can't fully act on it anymore.
The week-six plateau
This is the practical tell, and it's common enough to be a pattern: strong, encouraging results from GHK-Cu in the first month or so, then a quiet stall somewhere around the six-week mark. There are several plausible explanations — receptor dynamics, the natural ceiling of any single input — but cofactor depletion is a clean and likely candidate, because it fits the timing and the mechanism. The program is still being signaled; the fuel to run it isn't keeping pace. Pairing GHK-Cu with NAD+ support is the obvious lever, and it's exactly why the two show up together in well-constructed stacks rather than as separate products people happen to buy.
Topical, injected, and the blue
GHK-Cu gets used two main ways: topically, for direct effects on skin, and subcutaneously, for a more systemic signal. Many people do both, treating them as different tools rather than competitors. And one reassurance for newcomers, because it surprises everyone the first time: GHK-Cu reconstitutes blue. When you add bacteriostatic water, the solution turns a clear, distinct blue. That is the copper in the molecule, not contamination, oxidation, or a sign the vial has gone bad. A blue solution is exactly what a correctly mixed GHK-Cu vial looks like.
Common questions
You don't have to, but it's the most logical pairing if you're chasing sustained results and you've noticed the typical plateau.
No. It's the copper in GHK-Cu. A clear blue solution is expected and correct.
Both are used. Topical targets skin directly; subcutaneous gives a more systemic signal. Many people use them together.
For research and educational purposes only. Not medical advice.